Dimensional Fund Advisors LP G1 Therapeutics, Inc. Transaction History

Dimensional Fund Advisors LP

$403 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$2.2 - $4.98 $5,951 - $13,470	-2,705 Reduced 3.49%	74,826 $170,000
Q1 2024 May 10, 2024	BUY	$2.1 - $4.83 $1,816 - $4,177	865 Added 1.13%	77,531 $334,000
Q4 2023 Feb 07, 2024	BUY	$1.12 - $3.73 $2,528 - $8,422	2,258 Added 3.03%	76,666 $233,000
Q3 2023 Nov 09, 2023	SELL	$1.22 - $2.67 $10,788 - $23,610	-8,843 Reduced 10.62%	74,408 $107,000
Q2 2023 Aug 09, 2023	SELL	$2.46 - $3.14 $14,469 - $18,469	-5,882 Reduced 6.6%	83,251 $207,000
Q1 2023 May 12, 2023	SELL	$2.57 - $8.16 $716,608 - $2.28 Million	-278,836 Reduced 75.78%	89,133 $238,000
Q4 2022 Feb 09, 2023	SELL	$5.19 - $13.5 $511,012 - $1.33 Million	-98,461 Reduced 21.11%	367,969 $2 Million
Q3 2022 Nov 10, 2022	SELL	$5.17 - $16.99 $369,949 - $1.22 Million	-71,557 Reduced 13.3%	466,430 $5.83 Million
Q2 2022 Aug 12, 2022	SELL	$4.04 - $8.51 $113,216 - $238,484	-28,024 Reduced 4.95%	537,987 $2.66 Million
Q1 2022 May 13, 2022	BUY	$7.6 - $11.02 $313,712 - $454,883	41,278 Added 7.87%	566,011 $4.3 Million
Q4 2021 Feb 09, 2022	SELL	$10.16 - $16.17 $656,315 - $1.04 Million	-64,598 Reduced 10.96%	524,733 $5.36 Million
Q3 2021 Nov 12, 2021	SELL	$13.16 - $22.47 $6.33 Million - $10.8 Million	-480,793 Reduced 44.93%	589,331 $7.91 Million
Q2 2021 Aug 12, 2021	BUY	$19.57 - $26.32 $4.4 Million - $5.92 Million	225,057 Added 26.63%	1,070,124 $23.5 Million
Q1 2021 May 14, 2021	BUY	$17.58 - $32.59 $4.42 Million - $8.2 Million	251,613 Added 42.4%	845,067 $20.4 Million
Q4 2020 Feb 25, 2021	BUY	$10.99 - $20.4 $6.52 Million - $12.1 Million	593,454 New	593,454 $10.7 Million

Others Institutions Holding GTHX

# of Institutions

Shares Held

3.62M

Call Options Held

11.7K

Put Options Held

View Full List

About G1 Therapeutics, Inc.

Ticker GTHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,746,800
Market Cap $306M
Description
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...

More about GTHX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.

Account